Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

Submitted by admin on March 24, 2021 - 10:16am
Source: 
Benzinga
News Tags: 
Myovant
Pfizer
clinical trials
Relugolix
uterine fibroids
Headline: 
Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids
snippet: 

Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uterine fibroids.

Do Not Allow Advertisers to Use My Personal information